Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2024, recent business highlights, and key upcoming milestones for 2024.

MENLO PARK, Calif., May 8, 2024 /PRNewswire/ -- Cyngn Inc. (the "Company" or "Cyngn") (Nasdaq: CYN) today announced its financial results for the fiscal first quarter ended March 31, 2024.

Patent, once issued, will provide composition protection through 2040, with potential for additional term extension Annamycin is advancing towards pivotal AML study in 2024 and may qualify for an accelerated approval pathway HOUSTON, May 9, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it has received an Issue Notification from the United States Patent and Trademark Office (USPTO) for U.S. Patent number 11,980,634 titled, "Method of Reconstituting Liposomal Annamycin" (the '634 patent') to be issued on May 14, 2024 ...

The Company is aware that a video relating to the Company has been released on a social media outlet in China by YT Jia, in his individual capacity and not in his capacity as an officer of the Company. The statements made in the video have not been approved by the Company and none of such statements should be attributed or attributable to the Company. Further, while the Company understands that the video indicates contemplation by Mr. Jia of the possibility of serving as co-Chief Executive Officer of the Company subject to appointment by the Company’s Board of Directors, and ...